...
首页> 外文期刊>South Asian Journal of Cancer >A prospective randomized study comparing concurrent chemoradiation with weekly and 3 weekly cisplatin in locally advanced oropharyngeal carcinoma
【24h】

A prospective randomized study comparing concurrent chemoradiation with weekly and 3 weekly cisplatin in locally advanced oropharyngeal carcinoma

机译:一项前瞻性随机研究比较了局部晚期咽喉癌的同期放化疗与每周和每周3次顺铂的同步性

获取原文
           

摘要

Introduction: The chemotherapy schedules with cytotoxic dose or weekly regimes are still challenging, weighing the benefits versus toxicities. This prospective randomized study is an attempt to assess the efficacy of two schedules of cisplatin in management of locally advanced HNSCC. Objectives: The objectives of this study was to evaluate tolerance, tumour response and toxicities of concurrent chemoradiation with cisplatin in weekly and three weekly regimes. Methods: Locally advanced oropharyngeal squamous cell carcinoma patients fit for concurrent chemoradiation with cisplatin 40 mg/m2 (weekly) and 100 mg/m2 (3 weekly) were randomized to Arm A and B concurrently with radiotherapy of 70Gy/35frs/7 weeks. Statistical Analysis: Chi-square/ Fisher Exact test has been used to find the significance of study parameters on categorical scale between the groups. The statistical software SPSS 15.0 was used. Results: Between December 2010 and January 2013, 60 patients were enrolled. The median cycles of cisplatin in Arm-A was 5 and 2 in Arm-B. The complete response of 80.9% vs 75% and partial response of 14.3% vs 12.5% was observed in both arms respectively. There was no statistical difference in acute radiation and hematological toxicities between the two groups. With median follow up of 28 months, the 2 and 5 years overall survival was 55% and 58%; 41.6% and 32.3% in arms A and B respectively. Conclusion: In our study of locally advanced oropharyngeal carcinoma treated with radical radiotherapy comparing concurrent chemotherapy with cisplatin weekly vs 3 weekly had no significant difference in overall response, complete response and acute toxicities.
机译:简介:带有细胞毒性剂量或每周方案的化疗方案仍然具有挑战性,权衡了益处与毒性。这项前瞻性随机研究旨在评估两种顺铂方案在局部晚期HNSCC治疗中的疗效。目的:本研究的目的是评估每周和每周三个疗程中顺铂同时放化疗的耐受性,肿瘤反应和毒性。方法:将适合局部放疗的局部晚期口咽鳞状细胞癌患者以顺铂40 mg / m2(每周)和100 mg / m2(每周3)进行同步放疗,并随机分配至A组和B组,同时放疗为70Gy / 35frs / 7周。统计分析:卡方检验/ Fisher精确检验已被用来发现研究参数在两组之间的分类量表上的重要性。使用统计软件SPSS 15.0。结果:2010年12月至2013年1月,共有60例患者入选。在Arm-A中,顺铂的中位周期为5,在Arm-B中为2。两组均观察到完全缓解分别为80.9%vs.75%和部分缓解为14.3%vs.12.5%。两组之间的急性放射和血液学毒性没有统计学差异。中位随访28个月,2年和5年总生存率分别为55%和58%; A组和B组分别为41.6%和32.3%。结论:在我们对接受局部放疗的局部晚期咽喉癌的研究中,每周一次与每周三次同时进行的顺铂化疗比较,总反应,完全反应和急性毒性无显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号